Pictured: a scientist working on machine learning models/gorodenkoff/iStock
As the number of employees laid off in the tech industry continues to grow, biopharma companies are increasingly recruiting talent who wish to transfer their skills to the life sciences.
Specifically, those with skills in artificial intelligence (AI) and machine learning (ML) are in high demand across…
AbbVie has agreed to discover and develop mRNA biology modulators for three targets in oncology and immunology by applying Anima Biotech’s mRNA Lightning platform, through an up to $582 million collaboration announced by the companies.
In return, Anima—an mRNA-based drug developer based in Bernardsville, NJ—has granted AbbVie exclusive rights to license and further develop and…
Anima will use its mRNA Lightning platform to discover novel mRNA biology modulators against the collaboration targets: providing AbbVie exclusive rights to license and further develop and commercialize the programs. Anima will receive an upfront payment of $42m and may be eligible to receive up to $540m in option fees and R&D milestones across the three targets,…
The collaboration will discover and develop mRNA biology modulators for three oncology and immunology targets. Credit: felixioncool / Pixabay.
…